Age-related Macular Degeneration - An Asian Perspective
暂无分享,去创建一个
[1] A. Ho. Effect of Lesion Size, Visual Acuity, and Lesion Composition on Visual Acuity Change With and Without Verteporfin Therapy for Choroidal Neovascularization Secondary To Age-Related Macular Degeneration: TAP and VIP Report No. 1 , 2004 .
[2] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[3] A. Augustin,et al. TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION: Verteporfin PDT, Bevacizumab, and Dexamethasone , 2007, Retina.
[4] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[5] S. Kelly,et al. Perceptions of blindness related to smoking: a hospital-based cross-sectional study , 2005, Eye.
[6] G. Peyman,et al. TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) , 2006, Retina.
[7] Simon P. Harding,et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. , 2001, American journal of ophthalmology.
[8] H. Wong,et al. Polypoidal choroidal vasculopathy causing massive suprachoroidal haemorrhage , 2007, Eye.
[9] I. Scott,et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study) , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.
[10] Sander R. Dubovy,et al. SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[11] J. Vander. Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration , 2007 .
[12] T. Tock. Age-related Macular Degeneration: An Emerging Challenge for Eye Care and Public Health Professionals in the Asia Pacific Region , 2006 .
[13] Peter K. Kaiser,et al. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .
[14] W. Willett,et al. A prospective study of cigarette smoking and age-related macular degeneration in women. , 1996, Journal of the American Medical Association (JAMA).
[15] London,et al. Treatment of senile disciform macular degeneration: a single-blind randomised trial by argon laser photocoagulation. The Moorfields Macular Study Group. , 1982, The British journal of ophthalmology.
[16] Jennifer I. Lim,et al. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.
[17] N. Bressler,et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.
[18] N. Bressler. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .
[19] I. Scott,et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. , 2006, Investigative ophthalmology & visual science.
[20] Richard F Spaide,et al. INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[21] R. Malach,et al. RESULTS OF A MULTICENTER CLINICAL TRIAL TO EVALUATE THE PREFERENTIAL HYPERACUITY PERIMETER FOR DETECTION OF AGE-RELATED MACULAR DEGENERATION , 2005, Retina.
[22] G. Shah,et al. COMBINED PHOTODYNAMIC THERAPY WITH VERTEPORFIN AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION , 2006, Retina.
[23] N. Bressler. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.
[24] R. Maturi,et al. ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT , 2006, Retina.
[25] T. Ciulla,et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. , 2006, Archives of ophthalmology.
[26] Michael Stur,et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. , 2003, American journal of ophthalmology.
[27] Emmett T. Cunningham,et al. VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .
[28] T. Lai,et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. , 2004, Ophthalmology.
[29] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[30] Neil M Bressler,et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.